Preclinical evaluation of a novel allosteric IL-1R inhibitor (rytvela) for the prevention of perinatal inflammation-induced fetal injury [ 2018 - 2021 ]

Research Grant

Researchers: Prof Jeffrey Keelan (Principal investigator) ,  A/Pr Matthew Kemp ,  Dr Hayley Dickinson ,  Prof David Olson ,  Prof Sarah Robertson

Brief description Interleukin-1 (IL-1) is a potent inflammatory protein involved in many inflammatory disorders, including preterm birth (PTB). Blocking the actions of IL-1 in pregnancies at risk of delivering preterm may protect the fetus from PTB and the long-term harm of exposure to inflammation before birth. Using four different models of antenatal inflammation, we will explore the use of a new IL-1 inhibitor to see if it blocks inflammation ‘in utero’ and improve neonatal health and development.

Funding Amount $AUD 1,397,116.98

Funding Scheme Project Grants

Notes Standard Project Grant